Communications Biology (Jul 2021)
Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis
- Subir Karmakar,
- Nevien Ismail,
- Fabiano Oliveira,
- James Oristian,
- Wen Wei Zhang,
- Swarnendu Kaviraj,
- Kamaleshwar P. Singh,
- Abhishek Mondal,
- Sushmita Das,
- Krishna Pandey,
- Parna Bhattacharya,
- Greta Volpedo,
- Sreenivas Gannavaram,
- Monika Satoskar,
- Sanika Satoskar,
- Rajiv M. Sastry,
- Timur Oljuskin,
- Telly Sepahpour,
- Claudio Meneses,
- Shinjiro Hamano,
- Pradeep Das,
- Greg Matlashewski,
- Sanjay Singh,
- Shaden Kamhawi,
- Ranadhir Dey,
- Jesus G. Valenzuela,
- Abhay Satoskar,
- Hira L. Nakhasi
Affiliations
- Subir Karmakar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Nevien Ismail
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Fabiano Oliveira
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH
- James Oristian
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH
- Wen Wei Zhang
- Department of Microbiology and Immunology, McGill University
- Swarnendu Kaviraj
- Gennova Biopharmaceuticals, Hinjawadi Phase II
- Kamaleshwar P. Singh
- Gennova Biopharmaceuticals, Hinjawadi Phase II
- Abhishek Mondal
- Rajendra Memorial Research Institute of Medical Sciences
- Sushmita Das
- Rajendra Memorial Research Institute of Medical Sciences
- Krishna Pandey
- Rajendra Memorial Research Institute of Medical Sciences
- Parna Bhattacharya
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Greta Volpedo
- Department of Pathology and Microbiology, Ohio State University
- Sreenivas Gannavaram
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Monika Satoskar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Sanika Satoskar
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Rajiv M. Sastry
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Timur Oljuskin
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Telly Sepahpour
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Claudio Meneses
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH
- Shinjiro Hamano
- Department of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University
- Pradeep Das
- Rajendra Memorial Research Institute of Medical Sciences
- Greg Matlashewski
- Department of Microbiology and Immunology, McGill University
- Sanjay Singh
- Gennova Biopharmaceuticals, Hinjawadi Phase II
- Shaden Kamhawi
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH
- Ranadhir Dey
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- Jesus G. Valenzuela
- Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH
- Abhay Satoskar
- Department of Pathology and Microbiology, Ohio State University
- Hira L. Nakhasi
- Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA
- DOI
- https://doi.org/10.1038/s42003-021-02446-x
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 14
Abstract
Karmakar et al produced a dermotropic, live attenuated centrin gene-deleted Leishmania major (LmCen −/− ) vaccine against Visceral Leishmaniasis (VL). They demonstrated in hamsters that a single intradermal injection confers robust and durable protection against lethal VL that is transmitted naturally via bites of L. donovani-infected sand flies.
